PHARMACEUTICAL 2014

Dendreon CORP
Rank 106 of 234



PHARMACEUTICAL 2014

Dendreon CORP
Rank 106 of 234

The relative strengths and weaknesses of Dendreon CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dendreon CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Dendreon CORP is the variable Expenses, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 30% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	283,748
Cost of Goods Sold	166,328
Intangible Assets	0
Liabilities, Current	103,761
Liabilities, Non-Current	0
Other Assets	25,485
Other Compr. Net Income	-68
Other Expenses	111,124
Other Liabilities	0
Other Net Income	582
Other Revenues	283,746
Property and Equipment	125,168
Research and Development	70,833
Selling, General and Administrative Expense	232,847

Output Variable	Value in 1000 USD
Assets	434,401
Liabilities	103,761
Expenses	581,132
Revenues	283,746
Stockholders Equity	330,640
Net Income	-296,804
Comprehensive Net Income	-296,838
BaseVar	701,845
ECR before LimitedLiability	158%
Economic Capital Ratio	273%